Post by REETA SELVARANI JESURAJ

Cataracts remain one of the world’s leading causes of vision loss, currently affecting more than 65 million people globally. For decades, surgical intervention to physically swap out the cloudy natural lens for a clear artificial implant has been the undisputed gold standard of care. However, an international team of scientists led by Professor Barbara Pierscionek at Anglia Ruskin University has pushed non-surgical alternatives into the spotlight by developing an advanced topical drug treatment. The team created an oxysterol compound known as VP1-001, which is engineered to directly target and break down the dense alpha-crystallin protein clumps that scatter light and compromise vision. In preclinical laboratory trials on mice, researchers applied the experimental compound as an eye drop directly to the ocular surface with highly encouraging optical results. The treatment successfully improved the refractive index profiles—the lens's core internal measurement needed to maintain high focusing capacity—in 61% of the tested subjects. Furthermore, advanced slit-lamp biomicroscopy and x-ray tomography confirmed a noticeable reduction in lens opacity and cloudiness across 46% of cases. These metrics suggest that the compound works by actively restoring the proper protein organization inside the lens tissue without requiring surgical entry. While this molecular breakthrough could eventually revolutionize affordable, accessible eye care worldwide, ophthalmologists emphasize that a public rollout remains far off. Cataracts have a multitude of distinct root causes, and initial data shows that VP1-001 is highly specific to certain genetic or protein-mutation strains, meaning it does not yet work for every type of lens clouding. Additionally, while the compound successfully treats underlying transparency, it cannot correct standard refractive errors like near or farsightedness. Extensive human clinical trials are required to prove both safety and identical efficacy in human eyes, but the progress marks a massive leap toward a drug-based future for vision restoration. Main VP1-001 study Wang et al. 2022, _Invest Ophthalmol Vis Sci Original mouse trial DOI: https://lnkd.in/g9GsYwAK PDF: https://lnkd.in/g_Vj527a bf98 26 mice treated, VP1-001 topical in one eye. *61% showed improved refractive index profiles*. *46% had lens opacity grade reduced by 1.0*. Uses X-ray tomography + slit-lamp. 3410 AAO summary with PDF American Academy of Ophthalmology 2022 review Download PDF: https://lnkd.in/gunvjiRU fa8a Mechanism of VP1-001, _IOVS_ 2023 PubMed: https://lnkd.in/gTMBBjKT Shows VP1-001 binds αB-crystallin stereoselectively; enantiomer ent-VP1-001 doesn’t work. 9b8d Important context: Authors stress VP1-001 works for _some_ cataract types only, not all. Human trials still needed. fa8a. REETA SRJts KFSH&RC - Riyadh KSA - PICU-Senior Nurse #CriticalCare#NursingEducation#ICUNurse #PatientSafety #NursingLeadership #NurseLife#